EXHIBIT 10.72
RESEARCH AND COMMERCIALIZATION AGREEMENT
THIS AGREEMENT is made this 24th day of February, 1997 (the "Effective
Date") by and between CENTOCOR, INC. ("Centocor"), a Pennsylvania corporation
with its principal executive offices at 000 Xxxxx Xxxxxx Xxxxxxx, Xxxxxxx,
Xxxxxxxxxxxx 00000-0000, and GENPHARM INTERNATIONAL, INC. ("GenPharm"), a
California corporation with its principal executive offices at 000 Xxxxxxxxxx
Xxxxxx, Xxxxx X, Xxxx Xxxx, Xxxxxxxxxx 00000.
RECITALS
A. Centocor wishes to have access to GenPharm's HuMAb-Mouse(TM) system
to enable it to recover and characterize human monoclonal antibodies resulting
from immunization of GenPharm's transgenic mice with specified antigens, and to
have an option to obtain an exclusive license to commercialize some or all of
such resulting antibodies.
B. The parties wish to set forth their agreement regarding the terms
and conditions upon which such access and option for a commercial license will
be provided to Centocor.
AGREEMENT
In consideration of their mutual promises and covenants, Centocor and
GenPharm, each intending to be legally bound, agree as follows:
ARTICLE I - DEFINITIONS
The following terms when used in this Agreement shall have the
respective meanings assigned to them below.
-----------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as "[*****]".
1.01 Affiliate of either party or other entity shall mean any
---------
corporation, firm, association or other legal entity that directly or
indirectly controls, is controlled by, or is under common control with,
such entity, but only for so long as said control continues. For purposes of
this definition, "control" means possession of the power, whether or not
normally exercised, to direct the management and affairs of an entity,
directly or indirectly, whether through the ownership of voting securities,
by contract or otherwise. In the case of a corporation, the direct or indirect
ownership of 50% or more of its outstanding voting shares shall in any
case be deemed to confer control, while the ownership of a lower
percentage of such securities shall not necessarily preclude the existence of
control.
1.02 Commercial Field shall mean the making, having made, use
----------------
and sale of Licensed Antibodies.
1.03 Commercial License shall have the meaning assigned to it in
------------------
Section 3.01.
1.04 GenPharm Know-How shall mean any information, data
-----------------
and/or materials possessed, acquired and/or developed by GenPharm on or
prior to the Effective Date or during the term of this Agreement relating
to the subject matter of the Research License (including immunization of
Transgenic Mice and generation of Resulting Antibodies) or the subject
matter of the Commercial License that are not generally known or
available.
1.05 GenPharrn Patent Rights shall mean any patents and/or patent
-----------------------
applications relating to the subject matter of the Research License
(including immunization of Transgenic Mice and generation of Resulting
Antibodies) or the subject matter of the Commercial License that GenPharm
now owns or controls or that GenPharm may come to own or control at
any time during the term of this Agreement, and any divisionals,
continuations, continuations-in-part or reissues of such patents or patent
applications. The GenPharm Patent Rights include the issued patents listed
2
on Attachment 1, and shall include all patent rights of GenPharm that are
necessary for commercialization of Licensed Antibodies.
For purposes of this definition, "control" by GenPharm of a patent
or patent application shall mean GenPharm's having the right to grant to
Centocor licenses or sublicenses thereunder within the Research Field or
the Commercial Field, without violating any rights of or obligations to
third parties. Control may arise through ownership or license or other
contractual rights.
1.06 Licensed Antibodies shall mean Resulting Antibodies covered
-------------------
by the Commercial License.
1.07 [*****]
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
3
occurs away from the premises of Centocor after Centocor has relinquished
possession.
1.09 Research Field shall mean immunization of Transgenic Mice with
--------------
Specified Antigens, and recovery and characterization of Resulting Antibodies,
for research purposes only, including preclinical and animal testing of
Resulting Antibodies.
1.10 Research License shall have the meaning assigned to it in
----------------
Section 2.01.
1.11 Resulting Antibodies shall mean human monoclonal antibodies
--------------------
resulting directly or indirectly from immunization of Transgenic Mice with
Specified Antigens in accordance with the Research License.
1.12 Specified Antigens shall mean the following antigens:[*****]
------------------
1.13 Transgenic Mice shall mean GenPharm proprietary transgenic mice
---------------
containing unrearranged human immunoglobulin genes.
ARTICLE II - RESEARCH LICENSE
2.01 License Grant. GenPharm hereby grants to Centocor a nonexclusive
-------------
research license, without sublicense rights, under the GenPharm Patent Rights
and the GenPharm Know-How within the Research Field (the "Research License").
The term of the Research License shall be one year, but shall be renewable for
an additional year by Centocor by notice given to GenPharm no later than 90 days
prior to the expiration of the initial term. GenPharm shall give to Centocor (at
Centocor's expense) such reasonable assistance as Centocor may request relative
to Centocor's activities under the Research License, and Centocor shall disclose
to GenPharm all data and information developed by Centocor in the course of such
activities.
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
4
2.02 Provision of Transgenic Mice. GenPharm shall provide Centocor
----------------------------
with up to ***** immunizable sterile Transgenic Mice per year of the then
current strain during the term of the Research License, with the first [*****]
such mice being shipped within 30 days after the Effective Date. If any such
mice die of natural causes before commencement of the immunization protocol or
for any reason during the immunization protocol, provided that their death was
not due to Centocor's misfeasance or negligence, they shall be replaced without
cost by GenPharm. Subsequent shipments of Transgenic Mice shall be in quantities
and at times to be agreed. Centocor shall not breed Transgenic Mice, use them
for any purpose other than activities under the Research License, or transfer
them to any other person or entity or to any place other than Centocor's
facilities in Malvern, Pennsylvania. Title to the Transgenic Mice shall at all
times remain with GenPharm. Upon expiration or termination of the Research
License Centocor shall return all Transgenic Mice to GenPharm, and, except as
otherwise provided in Section 3.02, shall destroy all Resulting Antibodies and
other biological materials derived from Transgenic Mice, and all cells capable
of producing Resulting Antibodies.
2.03 Injunctive Relief. Centocor acknowledges that limitations and
-----------------
restrictions on its possession and use of Transgenic Mice and other biological
materials hereunder are necessary and reasonable to protect GenPharm, and
expressly agrees that monetary damages would be inadequate to compensate
GenPharm for any violation by Centocor of any such limitations or restrictions.
Centocor acknowledges that any such violation would cause irreparable injury to
GenPharm and agrees that, in addition to any other remedies that may be
available in law, in equity or otherwise, GenPharm shall be entitled to obtain
temporary and permanent injunctive relief against any threatened violation of
such limitations or restrictions or the continuation of any such violation in
any court of competent jurisdiction, without the necessity of proving actual
damages.
2.04 Ownership of Inventions. Any inventions made by Centocor or its
-----------------------
employees, consultants or agents in the course of activities under the Research
License that are or relate to cells, antibodies, genes, DNA sequences or other
biological materials derived directly or indirectly from
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
5
Transgenic Mice shall be owned by GenPharm, subject to the provisions of Article
III should Centocor obtain a commercial license. All other such inventions shall
be owned by Centocor.
2.05 License Fee. In consideration of the Research License, Centocor
-----------
shall pay GenPharm an annual license fee of [*****] during the term of the
Research License. The license fee for the initial one year term of the Research
License shall be due and payable on the Effective Date, and the license fee for
the renewed term of the Research License, if Centocor exercises its right for a
renewed term, shall be due and payable on the first day of the renewed term.
ARTICLE III - OPTION FOR COMMERCIAL LICENSE
3.01 License. GenPharm hereby grants to Centocor and its Affiliates the
-------
option to obtain an exclusive (even as to GenPharm), worldwide license, without
sublicense rights, under the GenPharm Patent Rights and the GenPharm Know-How
within the Commercial Field as to one or more Resulting Antibodies derived from
immunization with Specified Antigens (the "Commercial License"), provided that
GenPharm has not granted any licenses to antibodies to that Specified Antigen
within the Commercial Field to third parties prior to Centocor's exercise of its
option, subject to the obligation of Centocor to make benchmark payments to
GenPharm in accordance with Section 3.04 and to pay royalties to GenPharm in
accordance with Section 3.05. The term of the Commercial License for each
Licensed Antibody shall commence on the date of Centocor's exercise of its
option for that Licensed Antibody, and continue until the earlier of [*****]
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
6
[*****]
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
7
[*****]
(b) Each payment of royalties shall be accompanied by a written
statement setting forth the calculation of Net Sales for the quarter by Licensed
Antibody, and the number or quantity of each Licensed Antibody sold during the
quarter.
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
8
(c) GenPharm shall have the right to cause an examination of all
relevant books and records of Centocor and its Affiliates to be made by an
independent accounting firm upon reasonable notice during regular business
hours and no more frequently than once for any year solely to verify information
necessary to assure the accuracy of Centocor's calculation and reporting of Net
Sales. The cost of such examinations shall be borne by GenPharm, except that if
the results of any such examination show an underpayment of royalties of 5% or
more in any calendar quarter, all costs of such examination shall be borne by
Centocor.
(d) Only one royalty shall be due and payable for the sale of a Licensed
Antibody, irrespective of the number of claims within the GenPharm Patent
Rights which cover the making, use or sale of such Licensed Antibody.
(e) Any tax required to be withheld by Centocor under the laws of any
foreign country for the account of GenPharm shall be promptly paid by Centocor
for and on behalf of GenPharm to the appropriate governmental authority, and
Centocor shall use its best efforts to furnish GenPharm with proof of payment of
such tax. Any such tax actually paid on GenPharm's behalf shall be deducted from
royalty payments due GenPharm.
[*****]
ARTICLE IV - REPRESENTATIONS, WARRANTIES AND
INDEMNITY
4.01 [*****]
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
9
[*****]
(b) Centocor represents and warrants to GenPharm that it has full power,
right and authority to enter into and carry out its obligations under this
Agreement.
4.02 Warranties Limitation. EXCEPT FOR THE EXPRESS WARRANTIES IN
---------------------
SECTION 4.01, GENPHARM MAKES NO WARRANTIES TO CENTOCOR, AND CENTOCOR MAKES NO
WARRANTIES TO GENPHARM, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF
LAW, STATUTORY OR OTHERWISE. GENPHARM SPECIFICALLY DISCLAIMS ANY IMPLIED
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NONINFRINGEMENT. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF ANY BREACH OF THIS AGREEMENT.
4.03 Disclaimer of Other Commitments. Nothing in this Agreement or
-------------------------------
other dealings between the parties shall be construed as, and GenPharm
disclaims, any: (i) warranty or representation by GenPharm as to the validity or
scope of any of the GenPharm Patent Rights; (ii) warranty or representation by
GenPharm that the practice by Centocor of the rights and licenses granted to
Centocor herein will not infringe the patent or other intellectual property
rights of any third party; (iii) obligation of GenPharm to bring or prosecute
any action or suit against third parties for patent infringement; or (iv) grant
by implication, estoppel or otherwise of a right or license under any patent or
other intellectual property rights of GenPharm other than the GenPharm Patent
Rights and the GenPharm Know-How.
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
10
ARTICLE V - PATENT PROSECUTION, ENFORCEMENT
AND INFRINGEMENT
5.01 Patent Prosecution.
------------------
(a) GenPharm shall take all action reasonably necessary and
appropriate to prosecute the patent applications within the GenPharm Patent
Rights, and all divisions, continuations or continuations-in-part thereof,
worldwide, to seek prompt issuance of all patents from such patent applications,
and to maintain all patents within the GenPharm Patent Rights (including
without limitation inventor's certificates) and all substitutions, extensions,
reissues and renewals thereof or therefor.
(b) GenPharm shall, to the extent practicable, keep Centocor
informed as to the status of each patent application and each patent within the
GenPharm Patent Rights, including without limitation providing copies of all
relevant written communications from and with all patent offices, and shall
consult with Centocor on all relevant responses to such patent offices
sufficiently in advance of submission of any such response to permit Centocor to
review such response and to provide comments to GenPharm for consideration for
inclusion by GenPharm into such response.
5.02 Patent Enforcement. During the term of any Commercial License,
------------------
GenPharm shall institute and conduct legal action as it deems appropriate in its
reasonable judgment against third party infringers of any of the GenPharm Patent
Rights within the Commercial Field relating to such Commercial License. GenPharm
shall not enter into any settlement agreement respecting alleged infringement
within the Commercial Field without the consent of Centocor, which consent shall
not be unreasonably withheld or delayed. GenPharm shall receive the full benefit
of any action it takes pursuant to this Section 5.02.
[*****]
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
11
[*****]
ARTICLE VI - TERM AND TERMINATION
6.01 Term and Termination. This Agreement shall be deemed to have become
--------------------
effective on the Effective Date, and shall expire upon expiration or termination
of the Research License or, if Centocor has exercised its option for a
Commercial License under Section 3.01, upon expiration or termination of the
Commercial License. This Agreement and the Research License and Commercial
License may be terminated:
(a) at any time, upon agreement of the parties;
(b) by Centocor, upon 90 days' prior written notice to GenPharm;
(c) by either party immediately, if the other party materially
defaults in the performance of any of its obligations hereunder and
such default continues uncured for a period of 30 days after the date
of written notice of such default.
6.02 Effect of Expiration or Termination. The expiration or
-----------------------------------
termination of this Agreement shall not affect the rights or obligations of
the parties that have accrued prior to such expiration or termination.
Article VII shall survive the expiration or termination of this Agreement.
ARTICLE VII - CONFIDENTIALITY
During the term of this Agreement and thereafter until the
expiration of five years from the end of the term of the Research License,
each party shall keep strictly confidential, and shall not use for any purpose
other than the matter hereof, any and all information and materials
received from the other party which the disclosing party designates as
confidential ("Confidential Information and Materials"). There shall not be
***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SEC.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
12
considered as Confidential Information and Materials any information or
materials which:
(a) is or are already part of the public domain at the time of
disclosure or generation under this Agreement or thereafter becomes
or become part of the public domain otherwise than by breach of this
confidentiality obligation;
(b) the receiving party can show by competent proof had already
come into its possession without violation of this Agreement at the time
of disclosure or generation under this Agreement; or
(c) is communicated by a third party which did not receive the same
directly or indirectly from either party or from any other party under a
binder of confidentiality.
Each party may disclose Confidential Information or Materials, with the
prior written approval of the original disclosing party, to third parties having
a valid need to know and who enter into confidentiality agreements with the
original disclosing party containing restrictions on further disclosure and use
no less stringent than the provisions of this Article VII, or as it deems
necessary
(i) in obtaining, maintaining, prosecuting or defending patents
in accordance with this Agreement and in prosecuting or defending
litigation;
(ii) in connection with clinical trials or as otherwise required
for obtaining regulatory approvals; or
(iii) in complying with applicable laws or regulations or
fulfilling the disclosure requirements of any securities regulatory
agency or securities exchange in the event of a securities offering by
it;
provided that it gives the original disclosing party prior notice of such
disclosure and takes reasonable actions to limit the disclosure.
Upon expiration or termination of this Agreement, each party shall
promptly deliver to the other party all records in its possession or control
containing Confidential Information furnished to it by, and all Confidential
Materials belonging to, the other party, other than an archival set to be
retained by its legal department for compliance purposes.
13
ARTICLE VIII - MISCELLANEOUS
8.01 Independent Contractor. Nothing in this Agreement is intended or
----------------------
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the parties. All activities by the parties
hereunder shall be performed by them as independent contractors. Neither party
shall incur any debts or make any commitments for or on behalf of the other
party, unless specifically authorized in writing by an officer of the other
party.
8.02 Risk. Centocor assumes any and all risks of personal injury or
----
property damage attributable to its negligent acts or omissions or those of
its officers, employees or agents. Centocor shall indemnify GenPharm and
its officers, directors, employees and agents against and hold it and them
harmless from any loss, damage, liability or expense (including legal costs)
resulting from Centocor's activities under the Research License or the
Commercial License.
8.03 Indemnification. Each party shall indemnify the other and its
---------------
Affiliates and their officers, directors, employees and agents against and hold
it and them harmless from any loss or damage incurred by the indemnified party
on account of any material misstatement or omission in the representations and
warranties of the indemnifying party set forth in Section 4.01, or arising out
of any breach of this Agreement by the indemnifying party. Centocor shall
indemnify GenPharm, its Affiliates and its sublicensees and their officers,
directors, employees and agents against and hold them harmless from any and all
claims to the extent that such claims arise out of Centocor's intentional
misconduct or negligence in the manufacture, use, distribution and/or sale of
Licensed Antibodies. Centocor shall assume any and all Product Liability with
respect to Licensed Antibodies that are distributed and/or sold by it.
8.04 Limitations on Assignment. Neither this Agreement nor any interest
-------------------------
hereunder shall be assignable by either party by operation of law or otherwise
without the prior written consent or agreement of the other, except to an
Affiliate or in connection with a merger with or the sale of all
14
or substantially all of its assets to any person or entity. This Agreement shall
inure to the benefit of and shall be binding upon the parties and their
successors and permitted assigns, and the name of a party appearing herein shall
be deemed to include the names of such party's successors and permitted assigns
to the extent necessary to carry out the intent of this Agreement. In the event
of a merger or sale of assets of GenPharm, the obligation of Centocor to
purchase GenPharm stock pursuant to Section 3.03 shall be converted to an
obligation to purchase corresponding stock of the surviving or acquiring
company.
8.05 Further Acts and Instruments. Each party agrees to execute,
----------------------------
acknowledge and deliver such further instruments and to do all such other acts
as may be necessary or appropriate to carry out the purpose and intent of this
Agreement.
8.06 Entire Agreement: Amendment. This Agreement constitutes and
---------------------------
contains the entire agreement of the parties with respect to its subject matter,
and supersedes all prior negotiations, correspondence, understandings and
agreements between the parties respecting the subject matter hereof. This
Agreement may be amended or modified or one or more provisions hereof may be
waived only by a written instrument signed by authorized officers of both
parties.
8.07 Severability. Whenever possible, each provision of this Agreement
------------
shall be interpreted in such a manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be prohibited
by or invalid under applicable law, said provision shall be ineffective only to
the extent of such prohibition or invalidity, without invalidating the remainder
of such provision or the remaining provisions of this Agreement.
8.08 Headings and Captions. The headings and captions contained in this
---------------------
Agreement are for convenience only, and are to be of no force or effect in
construing and interpreting the provisions of this Agreement.
15
8.09 Disputes. Any and all claims, disputes or controversies arising
--------
under, out of, or in connection with this Agreement which have not been resolved
by good faith negotiations between the parties, shall be resolved by final and
binding arbitration under the Licensing Agreement Arbitration Rules of the
American Arbitration Association then obtaining. The arbitration shall take
place in San Francisco, California if invoked by Centocor or in Philadelphia,
Pennsylvania if invoked by GenPharm. The arbitrators shall have no power to add
to, subtract from or modify any of the terms or conditions of this Agreement.
Any award rendered in such arbitration may be enforced by either party in a
federal district court sitting in the Northern District of the State of
California or in the Eastern District of Pennsylvania, to whose jurisdiction for
such purposes the parties each hereby irrevocably consent and submit.
The parties agree that the arbitrators shall have no authority to award
injunctive or other equitable relief, including punitive or exemplary damages
against either party. Notwithstanding their agreement to submit, or any
submission of, their disputes to binding arbitration, the parties shall be free
to seek injunctive or other equitable relief in a federal district court sitting
in the Northern District of the State of California or in the Eastern District
of Pennsylvania, to whose jurisdiction for such purposes the parties each hereby
irrevocably consent and submit.
8.10 No Waiver for Failure to Enforce Compliance. Failure of either
-------------------------------------------
party to insist upon strict observance of or compliance with any of the terms of
this Agreement in one or more instances shall not be deemed to be a waiver of
its rights to insist upon observance of or compliance with such term thereafter,
or with any of the other terms of this Agreement. If either party wishes to
waive any of its rights hereunder, it shall do so in writing delivered to the
other party.
8.11 No Trademark or Trade Name License. Neither party shall have any
----------------------------------
right to use, for advertising, publicity or other commercial purposes, the name
or any trade name or trademarks, or contraction, abbreviation or simulation
thereof, of the other party without the latter's prior written consent.
16
8.12 No Announcements. Neither party shall make any announcements or
----------------
otherwise make public any information concerning this Agreement or either
party's business dealings with the other except as approved by the other, which
approval shall not unreasonably be withheld; provided, however, that either
party may disclose such information in complying with applicable laws or
regulations or fulfilling the disclosure requirements of any securities
regulatory agency or securities exchange in the event of a securities offering
by it. It is intended by the parties that a mutually agreed announcement
regarding the execution of this Agreement shall be made shortly after the date
of such execution.
8.13 Notices. Any notice, report, request, approval, payment, consent or
-------
other communication required or permitted to be given under this Agreement
shall be in writing and shall, for all purposes, be deemed to be fully given and
received if delivered in person or by overnight courier to the respective
parties at their respective addresses set forth at the head of this Agreement.
Either party may change its address for the purpose of this Agreement by
giving the other party written notice of its new address.
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed in duplicate by their respective authorized officers.
CENTOCOR, INC.
By: /s/ Xxxxx X. Xxxxxxx
------------------------------
Name: Xxxxx X. Xxxxxxx
----------------------------
Title: President and
Chief Executive Officer
---------------------------
Date: 2-25-97
---------------------------
GENPHARM INTERNATIONAL,
INC.
By: /s/ Xxxxxxxx XxxXxxxxx
----------------------------
Name: Xxxxxxxx XxxXxxxxx
----------------------------
Title: CEO
---------------------------
Date: 2/25/97
---------------------------
17
ATTACHMENT I
GENPHARM INTERNATIONAL
U.S. SERIAL
PATENT APPLICATION INVENTORS ASSIGNEE NO/PATENT NO.
1. Transgenic Non-Human Xxxxxxx, Xxx GenPharm International 5,545,806
Animals for Producing August 13, 1996
Heterologous
Antibodies
2. Transgenic Non-Human Xxxxxxx, Xxx GenPharm International 5,569,825
Animals Capable of October 29, 1996
Producing Heterologous
Antibodies of Various
Isotypes
3. Transgenic Mice Xxxxxxxxxxx, Xxxxx GenPharm International 5,591,669
Depleted in a Mature January 7, 1997
Lymphocytic Cell-Type
18
